{"id":30171,"date":"2025-03-24T17:34:58","date_gmt":"2025-03-24T09:34:58","guid":{"rendered":"https:\/\/flcube.com\/?p=30171"},"modified":"2025-03-24T17:34:59","modified_gmt":"2025-03-24T09:34:59","slug":"hainan-poly-pharm-faces-delisting-after-csrc-imposes-strict-penalties-for-financial-misconduct","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=30171","title":{"rendered":"Hainan Poly Pharm Faces Delisting After CSRC Imposes Strict Penalties for Financial Misconduct"},"content":{"rendered":"\n

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630<\/a>) was imposed strict administrative penalties by the China Securities Regulatory Commission (CSRC) last week. This action has triggered a delisting process by the Shenzhen Stock Exchange. The penalties were imposed after significant false records were discovered in Poly Pharm’s 2021 and 2022 annual reports. The company was found to have inflated profits by over RMB 500 million (USD 69 million) for two consecutive years, accounting for more than 50% of the total.<\/p>\n\n\n\n

Company Background<\/strong>
Founded in 1992, Hainan Poly Pharm is a leading injectables manufacturer in China. The company’s product portfolio includes antibiotics, anti-allergic drugs, nonsteroidal anti-inflammatory drugs, and other pharmaceutical products. Its main product, the desloratadine franchise, once achieved a market share exceeding 70% in China, highlighting its significant presence in the domestic pharmaceutical market.<\/p>\n\n\n\n

Impact and Implications<\/strong>
The administrative penalties and delisting process mark a critical moment for Hainan Poly Pharm. The company’s financial misconduct has not only led to severe regulatory consequences but also raises concerns about corporate governance and transparency in the Chinese pharmaceutical sector. Investors and stakeholders will be closely monitoring the company’s next steps as it navigates this challenging period.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) was imposed strict administrative penalties by the…<\/p>\n","protected":false},"author":1,"featured_media":30172,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,61],"tags":[474,1234],"class_list":["post-30171","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-legal-ip","tag-poly-pharm","tag-she-300630"],"yoast_head":"\nHainan Poly Pharm Faces Delisting After CSRC Imposes Strict Penalties for Financial Misconduct - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) was imposed strict administrative penalties by the China Securities Regulatory Commission (CSRC) last week. This action has triggered a delisting process by the Shenzhen Stock Exchange. The penalties were imposed after significant false records were discovered in Poly Pharm's 2021 and 2022 annual reports. The company was found to have inflated profits by over RMB 500 million (USD 69 million) for two consecutive years, accounting for more than 50% of the total.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=30171\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hainan Poly Pharm Faces Delisting After CSRC Imposes Strict Penalties for Financial Misconduct\" \/>\n<meta property=\"og:description\" content=\"China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) was imposed strict administrative penalties by the China Securities Regulatory Commission (CSRC) last week. This action has triggered a delisting process by the Shenzhen Stock Exchange. The penalties were imposed after significant false records were discovered in Poly Pharm's 2021 and 2022 annual reports. The company was found to have inflated profits by over RMB 500 million (USD 69 million) for two consecutive years, accounting for more than 50% of the total.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=30171\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-24T09:34:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-24T09:34:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2406-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30171#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30171\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hainan Poly Pharm Faces Delisting After CSRC Imposes Strict Penalties for Financial Misconduct\",\"datePublished\":\"2025-03-24T09:34:58+00:00\",\"dateModified\":\"2025-03-24T09:34:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30171\"},\"wordCount\":207,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30171#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2406-png.webp\",\"keywords\":[\"Poly Pharm\",\"SHE: 300630\"],\"articleSection\":[\"Company\",\"Legal \\\/ IP\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30171#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30171\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=30171\",\"name\":\"Hainan Poly Pharm Faces Delisting After CSRC Imposes Strict Penalties for Financial Misconduct - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30171#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30171#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2406-png.webp\",\"datePublished\":\"2025-03-24T09:34:58+00:00\",\"dateModified\":\"2025-03-24T09:34:59+00:00\",\"description\":\"China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) was imposed strict administrative penalties by the China Securities Regulatory Commission (CSRC) last week. This action has triggered a delisting process by the Shenzhen Stock Exchange. The penalties were imposed after significant false records were discovered in Poly Pharm's 2021 and 2022 annual reports. The company was found to have inflated profits by over RMB 500 million (USD 69 million) for two consecutive years, accounting for more than 50% of the total.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30171#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30171\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30171#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2406-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2406-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hainan Poly Pharm Faces Delisting After CSRC Imposes Strict Penalties for Financial Misconduct\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30171#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hainan Poly Pharm Faces Delisting After CSRC Imposes Strict Penalties for Financial Misconduct\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hainan Poly Pharm Faces Delisting After CSRC Imposes Strict Penalties for Financial Misconduct - Insight, China's Pharmaceutical Industry","description":"China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) was imposed strict administrative penalties by the China Securities Regulatory Commission (CSRC) last week. This action has triggered a delisting process by the Shenzhen Stock Exchange. The penalties were imposed after significant false records were discovered in Poly Pharm's 2021 and 2022 annual reports. The company was found to have inflated profits by over RMB 500 million (USD 69 million) for two consecutive years, accounting for more than 50% of the total.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=30171","og_locale":"en_US","og_type":"article","og_title":"Hainan Poly Pharm Faces Delisting After CSRC Imposes Strict Penalties for Financial Misconduct","og_description":"China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) was imposed strict administrative penalties by the China Securities Regulatory Commission (CSRC) last week. This action has triggered a delisting process by the Shenzhen Stock Exchange. The penalties were imposed after significant false records were discovered in Poly Pharm's 2021 and 2022 annual reports. The company was found to have inflated profits by over RMB 500 million (USD 69 million) for two consecutive years, accounting for more than 50% of the total.","og_url":"https:\/\/flcube.com\/?p=30171","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-24T09:34:58+00:00","article_modified_time":"2025-03-24T09:34:59+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2406-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=30171#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=30171"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hainan Poly Pharm Faces Delisting After CSRC Imposes Strict Penalties for Financial Misconduct","datePublished":"2025-03-24T09:34:58+00:00","dateModified":"2025-03-24T09:34:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=30171"},"wordCount":207,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=30171#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2406-png.webp","keywords":["Poly Pharm","SHE: 300630"],"articleSection":["Company","Legal \/ IP"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=30171#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=30171","url":"https:\/\/flcube.com\/?p=30171","name":"Hainan Poly Pharm Faces Delisting After CSRC Imposes Strict Penalties for Financial Misconduct - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=30171#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=30171#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2406-png.webp","datePublished":"2025-03-24T09:34:58+00:00","dateModified":"2025-03-24T09:34:59+00:00","description":"China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) was imposed strict administrative penalties by the China Securities Regulatory Commission (CSRC) last week. This action has triggered a delisting process by the Shenzhen Stock Exchange. The penalties were imposed after significant false records were discovered in Poly Pharm's 2021 and 2022 annual reports. The company was found to have inflated profits by over RMB 500 million (USD 69 million) for two consecutive years, accounting for more than 50% of the total.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=30171#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=30171"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=30171#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2406-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2406-png.webp","width":1080,"height":608,"caption":"Hainan Poly Pharm Faces Delisting After CSRC Imposes Strict Penalties for Financial Misconduct"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=30171#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hainan Poly Pharm Faces Delisting After CSRC Imposes Strict Penalties for Financial Misconduct"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2406-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30171","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30171"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30171\/revisions"}],"predecessor-version":[{"id":30173,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30171\/revisions\/30173"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/30172"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30171"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30171"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}